Immunocore (NASDAQ:IMCR) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of Immunocore (NASDAQ:IMCR) from a hold rating to a buy rating in a report issued on Saturday morning.

Other equities analysts also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Wednesday, October 22nd. Guggenheim started coverage on shares of Immunocore in a research note on Thursday, September 18th. They set a “neutral” rating for the company. Jefferies Financial Group began coverage on shares of Immunocore in a research report on Monday, August 25th. They set a “buy” rating and a $48.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Wednesday, October 8th. Finally, Wells Fargo & Company initiated coverage on Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Immunocore has a consensus rating of “Moderate Buy” and an average target price of $60.89.

Immunocore Stock Up 6.0%

NASDAQ:IMCR traded up $1.91 during trading hours on Friday, reaching $33.50. The company’s stock had a trading volume of 334,016 shares, compared to its average volume of 313,066. The stock has a 50 day moving average price of $33.83 and a two-hundred day moving average price of $33.18. The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.86 and a current ratio of 5.89. The company has a market capitalization of $1.69 billion, a P/E ratio of -58.77 and a beta of 0.78. Immunocore has a 12 month low of $23.15 and a 12 month high of $39.33.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.32. The business had revenue of $135.80 million for the quarter, compared to the consensus estimate of $137.29 million. Immunocore had a negative return on equity of 7.77% and a negative net margin of 7.70%.The business’s revenue was up 29.2% compared to the same quarter last year. During the same period last year, the business posted $0.17 EPS. Equities analysts predict that Immunocore will post -0.94 EPS for the current fiscal year.

Insider Transactions at Immunocore

In other news, insider David M. Berman sold 22,532 shares of the business’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Immunocore

A number of large investors have recently bought and sold shares of the business. Envestnet Asset Management Inc. increased its position in shares of Immunocore by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 67,259 shares of the company’s stock valued at $1,996,000 after buying an additional 735 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Immunocore by 0.4% during the first quarter. Massachusetts Financial Services Co. MA now owns 460,751 shares of the company’s stock worth $13,670,000 after acquiring an additional 1,706 shares during the period. Assetmark Inc. boosted its position in Immunocore by 4.8% during the first quarter. Assetmark Inc. now owns 33,710 shares of the company’s stock worth $1,000,000 after acquiring an additional 1,539 shares during the last quarter. Fiera Capital Corp grew its stake in Immunocore by 3.2% during the 1st quarter. Fiera Capital Corp now owns 805,150 shares of the company’s stock valued at $23,889,000 after acquiring an additional 25,186 shares in the last quarter. Finally, Primecap Management Co. CA raised its holdings in Immunocore by 0.4% in the 1st quarter. Primecap Management Co. CA now owns 2,678,650 shares of the company’s stock valued at $79,476,000 after acquiring an additional 10,100 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.